<DOC>
	<DOC>NCT02503683</DOC>
	<brief_summary>The purpose of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered ALN-AAT in Healthy Adult Subjects and Patients with ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease.</brief_summary>
	<brief_title>A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>Adequate complete blood counts, liver and renal function. 12lead electrocardiogram (ECG) within normal limits Female subjects must be of nonchildbearing potential; e.g. postmenopausal or premenopausal with surgical sterilization Male subjects agree to use appropriate contraception Willing to provide written informed consent and willing to comply with study requirements Nonsmokers for at least 5 years before screening Any uncontrolled or serious disease, or any medical or surgical condition, that may interfere with participation in the clinical study and/or put the subject at significant risk Received an investigational agent within 90 days before the first dose of study drug or are in followup of another clinical study Active serious mental illness or psychiatric disorder requiring current pharmacological intervention History or evidence of alcohol or drug abuse within 12 months before screening. History of intolerance to SC injection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>RNAi therapeutic</keyword>
	<keyword>AAT</keyword>
	<keyword>Alpha-1 Antitrypsin Deficiency</keyword>
</DOC>